Centauri Therapeutics Extends Series A to £30 Million with New…

Team S · 2026-02-26T13:00:05.000Z

Centauri Therapeutics, a Cheshire-based immunotherapy company specialising in advanced treatments for infectious diseases, has extended its Series A funding round to £30 million with a fresh £6 million investment from the AMR Action Fund. The new capital will help accelerate the progression of its lead clinical asset through key stages of clinical development. The company’s lead candidate, CTX-187, is part of Centauri’s ABX-01 programme and is currently under development ahead of first-in-human studies targeting multidrug-resistant Gram-negative infections a major unmet need in global health. The added Series A funding will support completion of Phase I clinical trials and expand research activities to prepare the asset for Phase II progression, generating essential safety data to inform future development. Funding Round and Investors – The Series A was extended by a £6 million investment from the AMR Action Fund, the world’s largest venture capital fund dedicated exclusively to antimicrobial therapeutics and diagnostics. As part of this investment, Dr Henni-Karoliina Ropponen, Venture Associate at AMR Action Fund, has been appointed to Centauri’s Board of Directors. The AMR Action Fund brings focused expertise and strategic support to accelerate Centauri’s programme. Centauri’s original Series A round, closed in January 2022, raised £24 million and included backing from Boehringer Ingelheim Venture Fund, Evotec SE, and Novo Holdings REPAIR Impact Fund. The company has also been supported by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) since 2019, helping push the ABX-01 programme from lead optimisation into preclinical development.

Member Login Get Access

Centauri Therapeutics Extends Series A to £30 Million with New… | Newnex